J
John Q. Trojanowski
Researcher at University of Pennsylvania
Publications - 1538
Citations - 245534
John Q. Trojanowski is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Dementia & Alzheimer's disease. The author has an hindex of 226, co-authored 1467 publications receiving 213948 citations. Previous affiliations of John Q. Trojanowski include Vanderbilt University & University of California, San Francisco.
Papers
More filters
Journal ArticleDOI
Divergent patterns of TDP-43 and tau pathologies in primary progressive aphasia.
Lucia A. A. Giannini,Lucia A. A. Giannini,Sharon X. Xie,Corey T. McMillan,Mendy Liang,Andrew Williams,Charles Jester,Katya Rascovsky,David A. Wolk,Sharon Ash,Edward B. Lee,John Q. Trojanowski,Murray Grossman,David J. Irwin +13 more
TL;DR: To measure postmortem burden of frontotemporal lobar degeneration with TDP‐43 (FTLD‐TDP) or tau (FT LD‐Tau) proteinopathy across hemispheres in primary progressive aphasia (PPA) using digital histopathology and to identify clinicopathological correlates of these distinct proteinopathies.
Journal ArticleDOI
α-Synuclein in Familial Alzheimer Disease: Epitope Mapping Parallels Dementia With Lewy Bodies and Parkinson Disease
TL;DR: These findings support the hypothesis that the mechanism of α-synuclein aggregation is the same within cell types but distinctive between cell types, and suggest that the epitope profiles in LBs are similar, regardless of whether the biological trigger is related to synuclein or a different genetic pathway.
Phosphorylated a-Synuclein in Parkinson's Disease
Yu Wang,Min Shi,Kathryn A. Chung,Cyrus P. Zabetian,James B. Leverenz,Daniela Berg,Karin Srulijes,John Q. Trojanowski,Y. Lee,Andrew Siderowf,Howard I. Hurtig,Irene Litvan,Mya C. Schiess,Elaine R. Peskind,Masami Masuda,Masato Hasegawa,Xiangmin Lin,Catherine Pan,Douglas Galasko,David S. Goldstein,Poul Henning Jensen,Kevin C. Cain,Jing Zhang +22 more
TL;DR: An assay for detecting phosphorylated α-synuclein in CSF may help to diagnose Parkinson’s disease and determine disease severity, and early results suggest that PS-129 may be useful as a marker to assist in the differential diagnosis of PD and to monitor disease progression.
Journal ArticleDOI
Monoclonal and polyclonal antibodies against neural antigens: Diagnostic applications for studies of central and peripheral nervous system tumors
Journal ArticleDOI
An Alzheimer’s Disease-Derived Biomarker Signature Identifies Parkinson’s Disease Patients with Dementia
Yosef Berlyand,Daniel Weintraub,Sharon X. Xie,Ian A. Mellis,Jimit Doshi,Jacqueline Rick,Jennifer D. McBride,Christos Davatzikos,Leslie M. Shaw,Howard I. Hurtig,John Q. Trojanowski,Alice Chen-Plotkin +11 more
TL;DR: Evaluated relationships among 17 biomarkers previously reported to associate with cognition in Parkinson’s disease or AD to test performance of a five-biomarker classifier trained to recognize AD in identifying PD with dementia (PDD), suggesting mechanisms shared with AD in some PDD patients.